JD Health (06618) shares surged 6.20% in Friday's trading session, as investors reacted positively to the company's impressive third-quarter financial results and strategic collaborations with major pharmaceutical firms.

The healthcare arm of Chinese e-commerce giant JD.com reported a stellar performance for Q3 2025. Revenue reached RMB 17.12 billion, marking a 28.7% year-on-year increase. More notably, the company's operating profit soared by 125.3% compared to the previous year, reaching RMB 1.243 billion. This significant profit growth has evidently boosted investor confidence in JD Health's business model and future prospects.

Adding to the positive sentiment, JD Health announced several strategic partnerships with renowned pharmaceutical companies. These collaborations include agreements with Lilly, Innovent Biologics, Eisai China, and Bayer China. The partnerships have already yielded tangible results, with new drugs such as Eisai's Dayvigo®, Hengrui's Hengqin®, and Bayer's Daxalt® being launched exclusively on JD Health's platform. Furthermore, the company has expanded its product offerings to include new health products from Haleon and a specialized medical food from Sheng Tong Medical Nutrition. These developments underscore JD Health's growing influence in the healthcare e-commerce space and its ability to attract high-profile partnerships, likely contributing to the stock's impressive performance.